An Open-Label, Multicenter Extension Study of Trastuzumab Emtansine Administered as a Single Agent or in Combination with other Anti-Cancer Therapies in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd–Sponsored Trastuzumab Emtansine Study

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-503479-79-00

Acronym

BO25430

Enrollment

Registered

2024-02-28

Start date

2011-06-17

Completion date

Unknown

Last updated

2025-12-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Metastatic Cancer

Brief summary

1. Incidence of adverse events leading to trastuzumab emtansine or combination treatment discontinuation or dose reduction., 2. Incidence of all adverse events and all serious adverse events

Interventions

DRUGKadcyla 160 mg powder for concentrate for solution for infusion.

DRUGTecentriq 1

DRUG200 mg concentrate for solution for infusion

DRUGPerjeta 420 mg concentrate for solution for infusion

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
1. Incidence of adverse events leading to trastuzumab emtansine or combination treatment discontinuation or dose reduction., 2. Incidence of all adverse events and all serious adverse events	—

Countries

Belgium, France, Poland, Portugal, Spain

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026